GlaxoSmithKline Teams with EMBL-EBI, Sanger Institute to Launch Target Validation Center | GenomeWeb

NEW YORK (GenomeWeb News) – In an effort to address the high failure rate of drug candidates in clinical studies, the Wellcome Trust Sanger Institute, the European Bioinformatics Institute, and GlaxoSmithKline have partnered to create a new center that will use genomics and big data technologies to validate drug targets, EMBL-EBI said today.

Based at the Wellcome Trust Genome Campus near Cambridge, the Centre for Therapeutic Target Validation (CTTV) will launch with a £1 million ($1.7 million) investment from GSK that will fuel its initial research projects.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.